NEW YORK (TheStreet) -- Perrigo (PRGO) - Get Report stock is down 0.80% to $156.29 in midday trading Tuesday after Deutsche Bank reduced its price target to $200 from $204, while maintaining a "buy" rating. 

"We believe investor sentiment remains poor," analysts said.

Deutsche Bank added that potential triggers for improved sentiment and performance for this year include sales and earnings growth acceleration following the close of the Omega Pharma of Belgium acquisition (in late March), and additional acquisitions that could bolster growth during the slow Consumer Healthcare launch period of fiscal years 2015 and 2016.

Exclusive Report:Jim Cramer's Best Stocks for 2015

Perrigo, a global healthcare supplier, reported fourth quarter earnings of $1.74 per share and fiscal year earnings of $6.39 per share in 2014.  

Analysts forecast earnings of $7.03 and $7.75 per share in 2015, and 2016, respectively. 

The company posted revenue of $4.06 billion in 2014.  Deutsche Bank expects the healthcare provider to post revenue of $4.35 billion in 2015 and $4.72 billion in 2016. 

Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

Separately, TheStreet Ratings team rates PERRIGO CO PLC as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:

"We rate PERRIGO CO PLC (PRGO) a BUY. This is driven by multiple strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

• The revenue growth came in higher than the industry average of 13.6%. Since the same quarter one year prior, revenues slightly increased by 9.4%. Growth in the company's revenue appears to have helped boost the earnings per share.
• The current debt-to-equity ratio, 0.49, is low and is below the industry average, implying that there has been successful management of debt levels. Along with this, the company maintains a quick ratio of 3.43, which clearly demonstrates the ability to cover short-term cash needs.
• The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 181.5% when compared to the same quarter one year prior, rising from -$86.10 million to $70.20 million.
• Net operating cash flow has significantly increased by 124.17% to $272.60 million when compared to the same quarter last year. In addition, PERRIGO CO PLC has also vastly surpassed the industry average cash flow growth rate of -17.72%.
• 47.67% is the gross profit margin for PERRIGO CO PLC which we consider to be strong. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 6.55% trails the industry average.
• You can view the full analysis from the report here: PRGO Ratings Report